title: In vivo investigations on the cholinesterase-inhibiting effects of tricyclic quinazolinimines: scopolamine-induced cognitive impairments in rats are attenuated at low dosage and reinforced at higher dosage.
abstract: Tricyclic quinazolinimines as a novel class of potent inhibitors of cholinesterases in vitro are micro- and sub-micromolar inhibitors with activities at both acetyl- (AChE) and butyrylcholinesterase (BChE) or at BChE only. To further establish the antiamnesic properties of this class of compounds, an in vivo test system has been established. Cognitive impairment in rats was reversibly induced by scopolamine (0.05 mg/100 g body weight) and evaluated in an eight-arm radial maze. A representative quinazolinimine (MD212) showed attenuation of cognitive deficits at a low dosage (0.01 mg/100 g body weight), whereas at a high dosage (>0.1 mg/100 g body weight) the effect of scopolamine is markedly reinforced. As MD212 applied alone does not influence rat's cognition at all, the reinforcement of scopolamine effect has to be due to the amplification of scopolamine action possibly by (1) inhibition of scopolamine metabolism, (2) influence of scopolamine on MD212 metabolism or (3) allosteric modulation of mACh receptors. Receptor-binding studies proved hypothesis (3): MD212 stabilizes [3H]N-methylscopolamine binding to muscarinic receptors allosterically.
authors: Institute of Pharmacology and Toxicology, Friedrich Schiller University Jena, Jena, Germany.
authors: D
authors: D
authors: Appenroth
authors: M
authors: M
authors: Decker
authors: C
authors: C
authors: Tränkle
authors: K
authors: K
authors: Mohr
authors: J
authors: J
authors: Lehmann
authors: C
authors: C
authors: Fleck
mesh_terms: D000494:Allosteric Regulation; D000818:Animals; D001392:Azocines / Q000494:pharmacology*; D018680:Cholinergic Antagonists / Q000494:pharmacology*; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D003071:Cognition / Q000187:drug effects; D003072:Cognition Disorders / Q000139:chemically induced / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005260:Female; D007097:Imines / Q000494:pharmacology; D018782:Maze Learning / Q000187:drug effects; D008570:Memory, Short-Term / Q000187:drug effects; D011799:Quinazolines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D012601:Scopolamine / Q000494:pharmacology*; D014316:Tritium
chemical_list: D001392:Azocines; D018680:Cholinergic Antagonists; D002800:Cholinesterase Inhibitors; D007097:Imines; C529219:N-benzyl-N-(6,7,8,9,10,11-hexahydro-13H-azocino(2,1-b)quinazolin-13-ylidene)amine; D011799:Quinazolines; D014316:Tritium; D012601:Scopolamine
references: Mol Pharmacol. 1989 May;35(5):652-60
references: 2725474
references: J Med Chem. 2006 Sep 7;49(18):5411-3
references: 16942014
references: Annu Rev Pharmacol Toxicol. 1986;26:161-81
references: 3087271
references: Mol Pharmacol. 2005 Dec;68(6):1597-610
references: 16157694
references: J Cereb Blood Flow Metab. 1996 Sep;16(5):973-80
references: 8784242
references: Pharmacol Biochem Behav. 1980 Apr;12(4):595-602
references: 7393955
references: Pharmacol Toxicol. 1988 Sep;63(3):163-8
references: 3054859
references: Eur J Pharmacol. 1998 May 22;349(2-3):137-42
references: 9671090
references: Neurochem Res. 1995 Jun;20(6):663-7
references: 7566361
references: Brain Res. 1994 Aug 8;653(1-2):231-6
references: 7982056
references: Behav Neural Biol. 1988 Nov;50(3):255-74
references: 3202811
references: J Neurol Neurosurg Psychiatry. 1999 Feb;66(2):137-47
references: 10071091
references: Pharmacol Biochem Behav. 1984 May;20(5):659-62
references: 6739511
references: Trends Pharmacol Sci. 1996 Aug;17(8):280-3
references: 8810873
references: J Am Osteopath Assoc. 2005 Mar;105(3):145-58
references: 15863734
references: Int J Neuropsychopharmacol. 2006 Feb;9(1):101-24
references: 16083515
references: J Neurochem. 1995 Feb;64(2):749-60
references: 7830069
references: J Mol Neurosci. 2006;30(1-2):165-8
references: 17192667
references: Curr Pharm Des. 2006;12(2):217-25
references: 16454738
references: Mol Pharmacol. 2005 Dec;68(6):1506-9
references: 16183853
references: J Neurochem. 2000 Jan;74(1):244-53
references: 10617126
references: Naunyn Schmiedebergs Arch Pharmacol. 2006 Jan;372(4):267-76
references: 16362429
references: Curr Mol Med. 2006 Jun;6(4):423-8
references: 16900665
references: J Cereb Blood Flow Metab. 1996 Sep;16(5):1014-25
references: 8784247
references: Biochem Pharmacol. 1991 Oct 24;42(10):1927-32
references: 1741770
references: Brain Res. 1995 Mar 6;673(2):290-6
references: 7606443
references: Eur J Pharmacol. 1994 Nov 24;265(3):151-8
references: 7875230
references: Farmakol Toksikol. 1986 May-Jun;49(3):37-40
references: 3720932
references: Expert Opin Ther Targets. 2007 Feb;11(2):161-79
references: 17227232
references: J Mol Neurosci. 2002 Aug-Oct;19(1-2):145-53
references: 12212772
references: Pharmacol Rev. 2002 Jun;54(2):323-74
references: 12037145
references: Bioorg Med Chem. 2006 Mar 15;14(6):1966-77
references: 16289855
references: Psychopharmacology (Berl). 2002 Jul;162(3):292-300
references: 12122487
references: Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1968;260(2):157-8
references: 4239195
references: Eur J Med Chem. 2005 Mar;40(3):305-13
references: 15725500
references: Alzheimer Dis Assoc Disord. 2006 Apr-Jun;20(2 Suppl 1):S12-8
references: 16772751
references: Jpn J Pharmacol. 2001 Nov;87(3):240-4
references: 11885975